Compare AbbVie Inc (ABBV) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares Self-Driving EV and Tech — how do they compare? AbbVie Inc trades at $254.13 (market cap $449.91B), while iShares Self-Driving EV and Tech trades at $36.18. The key difference: AbbVie Inc pays a 2.72% dividend while iShares Self-Driving EV and Tech pays none, and AbbVie Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| ABBV | IDRV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $45.48 |
52-Week Low | $184.85 | $31.81 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
IDRV trades at $38.51, up 2.01% today, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The ETF faces industry headwinds as rising fuel prices boost EV demand globally while US market adoption lags. Recent news highlights competitive threats from Chinese EV makers expanding internationally and regulatory uncertainty around US-China trade policies.
The ETF's outlook is challenged by sector volatility and geopolitical risks, though global EV adoption trends provide long-term growth potential. Key risks include tariff policy changes and slower-than-expected US EV adoption. Investors should monitor quarterly flows and sector performance for directional cues amid mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
